NCT06063291 - Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

July 11, 2024

Study Completion Date

July 11, 2024

Conditions

Healthy Adult Subjects

Interventions

DRUG

ID110521156

subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1

DRUG

Placebo of ID110521156

subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1

Trial Locations (1)

Seoul National University Hospital, Seoul